Repros Therapeutics (RPRX) 1.70 $RPRX Repros Provides

New Post Public Reply Private Reply Replies (0) Message Board

Jun 11, 2016 at 6:18 PM

Repros Therapeutics (RPRX) 1.70 $RPRX

Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
GlobeNewswire - Wed Jun 01, 3:01PM CDT
-- EU submission on track with anticipated registration decision expected Fall 2017
RPRX: 1.70 (-0.08)

Repros Reports Positive Clinical Data for Oral Proellex(R) in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
GlobeNewswire - Wed May 18, 3:01PM CDT
-- Primary endpoint of induction of amenorrhea met for the pooled oral doses compared to placebo, p=0.0004
RPRX: 1.70 (-0.08)

Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board
GlobeNewswire - Mon May 16, 3:00PM CDT
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced that it has appointed Mr. Patrick Fourteau to its Board of Directors, where he will serve as Chairman of the Board.
INSY: 13.99 (-2.04), RPRX: 1.70 (-0.08)

Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 37.14 (-0.37), ARQL: 1.78 (unch), APRI: 0.41 (-0.01), RPRX: 1.70 (-0.08)

Repros Therapeutics reports 1Q loss
Automated Insights - Tue May 10, 8:19AM CDT
WOODLANDS, Texas (AP) _ Repros Therapeutics Inc. (RPRX) on Tuesday reported a loss of $4.8 million in its first quarter.
RPRX: 1.70 (-0.08)

Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 38.40 (-0.47), BIIB: 246.13 (-4.33), CNAT: 2.02 (-0.11), AMGN: 154.78 (-2.00), RPRX: 1.70 (-0.08), JNJ: 117.01 (+0.01), GILD: 84.45 (-1.32), GWPH: 89.69 (+0.24), GERN: 2.77 (-0.04), AVEO: 1.03 (-0.03), ICPT: 150.66 (-3.56), AGIO: 50.35 (-5.87), NVS: 78.94 (-1.57)

Will Repros Therapeutics (RPRX) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:56AM CDT
As of late, it has definitely been a great time to be an investor in Repros Therapeutics Inc. (RPRX).
RPRX: 1.70 (-0.08)

Repros (RPRX) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue May 03, 8:25AM CDT
With no approved products in its portfolio, investors will be focused on Repros' progress with its pipeline candidates as well as its cost projections.
OVAS: 5.72 (-0.40), JAZZ: 150.76 (-5.26), RPRX: 1.70 (-0.08), CHMA: 2.91 (-0.23)

These Four Biotech Stocks Are Trading With Massive Volume Today
ACCESSWIRE - Tue Apr 19, 9:05AM CDT
NEW YORK, NY / ACCESSWIRE / April 19, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. SGYP, RPRX, CPXX and HRTX are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CPXX: 30.24 (+0.08), SGYP: 3.97 (-0.03), HRTX: 19.17 (-0.42), RPRX: 1.70 (-0.08)

Trending Stocks: Investors Have Found Interest In These Four Nasdaq Stocks on Monday
ACCESSWIRE - Mon Apr 18, 11:35AM CDT
MIAMI, FL / ACCESSWIRE / April 18, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. RPRX, COOL, CLMT, and UNXL have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
UNXL: 1.48 (-0.04), COOL: 0.88 (unch), RPRX: 1.70 (-0.08), CLMT: 5.06 (-0.38)

Trending Stocks: Thursday's Top Trading Stock Investors Have Followed
ACCESSWIRE - Thu Apr 14, 11:07AM CDT
MIAMI, FL / ACCESSWIRE / April 14, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. COOL, SUNE, RPRX, and EXXI have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
EXXI: 0.13 (-0.01), COOL: 0.88 (unch), SUNE: 0.34 (unch), RPRX: 1.70 (-0.08)

4 Small Cap Stocks That Have To Be On Your Watchlist Today
ACCESSWIRE - Thu Apr 14, 7:30AM CDT
NEW YORK, NY / ACCESSWIRE / April 14, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. RPRX, FELP, CLDX and FNJN are on high volume alert. We have been following RPRX and FELP all week this week. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CLDX: 4.12 (-0.20), RPRX: 1.70 (-0.08), FNJN: 1.69 (-0.06), FELP: 1.91 (+0.07)

Repros Therapeutics (RPRX) Announces Significant Data for Proellex Phase 2 Meeting with the FDA to Jointly Discuss Plans for Phase 3
ACCESSWIRE - Wed Apr 13, 12:28PM CDT
THE WOODLANDS, TX / ACCESSWIRE / April 13, 2016 / Repros Therapeutics Inc.® (NASDAQ: RPRX) reported that vaginal administration of Proellex at doses of both 6 and 12 mg achieved significant reduction in excessive menstrual bleeding, the key symptom of uterine fibroids.
RPRX: 1.70 (-0.08)

Repros Reveals Positive Data on Proellex for Uterine Fibroids
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 11:30AM CDT
Repros (RPRX) reported positive data from a phase IIb study on Proellex (vaginal administration) for the treatment of women suffering from uterine fibroids.
EBS: 42.30 (-1.19), RPRX: 1.70 (-0.08), AMAG: 21.04 (-0.82), ANIK: 49.16 (+0.24)

These Small Cap Stocks Are Getting Big Time Attention Today
ACCESSWIRE - Wed Apr 13, 9:50AM CDT
NEW YORK, NY / ACCESSWIRE / April 13, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. RPRX, FELP, EMKR and SUNE are on high volume alert. Continue reading to find out why these stocks are getting so much interest today. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
EMKR: 5.67 (+0.07), SUNE: 0.34 (unch), RPRX: 1.70 (-0.08), FELP: 1.91 (+0.07)

Repros Reports Positive Clinical Data for Vaginal Proellex(R) in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
GlobeNewswire - Tue Apr 12, 3:01PM CDT
-- Primary endpoint of induction of amenorrhea met for both vaginal doses compared to placebo, p<0.0011
RPRX: 1.70 (-0.08)

Apricus Hits 52-Week Low on Unfavorable Fispemifene Data
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 1:00PM CDT
Apricus' (APRI) shares hit a new 52-week low on disappointing top-line results from a phase IIb proof-of-concept study on fispemifene.
EBS: 42.30 (-1.19), APRI: 0.41 (-0.01), RPRX: 1.70 (-0.08), AMAG: 21.04 (-0.82)

Repros Gives EU Update on Secondary Hypogonadism Drug
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 4:05PM CDT
Repros Therapeutics (RPRX) announced that it has initiated the process for obtaining marketing authorization for enclomiphene by the European Medicines Agency.
AGN: 240.93 (-6.47), RPRX: 1.70 (-0.08), ABBV: 61.00 (+0.25)

Repros Announces Initiation of Formal Approval Process by the European Medicines Agency
GlobeNewswire - Tue Mar 15, 3:01PM CDT
Repros Therapeutics Inc.(R) (Nasdaq:RPRX) today announced that it has formally activated the process for obtaining marketing authorization for enclomiphene in the treatment of secondary hypogonadism by the European Medicines Agency (EMA).
RPRX: 1.70 (-0.08)

Repros Incurs Narrower-than-Expected Loss in Q4, Shares Up
Zacks Equity Research - Zacks Investment Research - Tue Mar 15, 8:40AM CDT
Repros Therapeutics (RPRX) reported a narrower-than-expected fourth-quarter 2015 loss of 26 cents per share.
RPRX: 1.70 (-0.08), AMAG: 21.04 (-0.82), ANIK: 49.16 (+0.24)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MoreBetter's Therapy Co-Investment: A Big Bet on Patient Data

Diving Into Uncharted Waters with Bold Moves MoreBetter is stepping right into the murky, unpredictable world of longevity, peptide, and psychedelic therapies with a fresh initiative—the RWE Co-Investment Program. This isn't your run-of-the-mill study announcement; it's a gutsy leap into largely unexplored areas of patient-reported outcomes and real-world evidence. A...

Jill De Forest Honored: A Journey Through Recruitment

A Force in Recruitment: Jill De Forest There's a name that reverberates through the corridors of executive search and recruitment: Jill De Forest. Recognized by The Inner Circle as the Pinnacle Professional of The Year, De Forest has left a profound mark on the industry with her knack for matching exceptional talent to major brands. Trailblazing through Executive Search...

Longevity Tour Hits East Coast: Brecka's Mission

Bringing Longevity to the East Coast This weekend, something interesting is happening on the East Coast of the U.S. Gary Brecka and his Ultimate Longevity Center (ULC) are holding a series of events in Philadelphia, New York, and Boston. Everything kicks off on November 14th. If the idea of 'live longevity' leaves you scratching your head, don’t worry—I've got you...

Solar Cooking Revolution: InventHelp's Latest Innovation

A Bright Idea Shines with Solar Cooking Some days, you stumble across an idea that just seems destined to shake things up, and COOK SOL SOLAR POWER COOKER might just be one of those spark plugs ready to ignite the world of outdoor cooking. Invented by a plucky thinker from Florence, South Carolina, this little gadget isn't just about frying up eggs on a camping trip. Nah,...

MemryX AI's MX3+ Chip: A Game Changer For AI Workloads

A New Benchmark in AI Acceleration Out of Ann Arbor, MemryX AI has thrown its hat into the ring with the latest in AI hardware wizardry—the MX3+ chip. Now this beige wonder promises to rev things up in the world of AI, boasting a tenfold increase in peak AI compute and upping the memory stakes by the same factor. All while sipping power like a polite fly at a soda...

OptiMantra's AI Scribe: Transforming Clinic Workflows

Cutting Through the Noise: AI Scribe's Pragmatic Impact OptiMantra's fresh launch of AI Scribe isn't just another gadget on the shelf—it's gunning for the throat of that time-sucking monster called after-hours charting. You'd think clinic management would be about patients first, right? But turns out, the devil's in the details, with docs burning midnight oil drafting...

Clarivate's IPOne Revolutionizes AI for IP Pros

A New Dawn for IP Intelligence: Clarivate's Strategic Move Seems like Clarivate's out to shake things up in the IP world. Today, they've announced that their coveted patent and litigation intelligence is now seamlessly integrated with AI workflows on Claude through IPOne. For those not neck-deep in patents and trademarks every day, let’s break it down. This means IP...

Ascletis Targets Obesity with New FDA Submission

Breaking Ground with Innovative Obesity Treatment In the world of biotech, where breakthroughs are hard-fought and the stakes can seem insurmountable, Ascletis Pharma is swinging for the fences with their latest maneuver. They've submitted an Investigational New Drug application to the U.S. Food and Drug Administration for ASC30_39 FDC—a pioneering fixed-dose combo pill...

Contract Workers Gain Traction in Workforce Planning

Contract Workers: The New Normal Ever feel like we're on a merry-go-round when it comes to workforce planning? Well, buckle up folks, because contract workers are becoming the mainstay of staffing strategies. According to a recent survey, 71% of U.S. companies are not just dabbling, but fully integrating these workers into their plans. That's a seismic shift from just a...

Goranson Bain Ausley Welcomes Marichalar: Family Law Focus

Strengthening San Antonio's Family Law Field Brenda Marichalar is joining the ranks at Goranson Bain Ausley (GBA) with a reputation built on solid courtroom chops and a knack for making clients feel like they’re more than just case numbers. She’s landing right in San Antonio, a region that’s not just about the riverwalks and missions, but about real families...